BACKGROUND: A study to analyse tumor markers (CEA, CA125, CA15.3, CA19.9, CYFRA 21-1, and NSE) for metastasis detection in lung cancer patients. METHODS: Serum tumor markers from 73 lung cancer patients were measured before they were diagnosed. After lung cancer diagnosis, tumor markers were analyzed for the detection of distant metastases. RESULTS: In NSCLC patients CYFRA 21-1 and NSE showed differences between stage IV and any of the other stages, p < 0.05. The accuracy for metastasis detection was AUC = 81.5 % for CYFRA 21-1 and AUC = 78.6 % for < 0.05) were independent predictors for metastasis presence. No tumor marker showed significant differences according to stages in SCLC patients. CONCLUSIONS: CYFRA 21-1 could be used as a screening tool for metastasis detection in lung cancer patients without symptoms of metastasis as well as CYFRA 21-1 and NSE in NSCLC patients.
BACKGROUND: A study to analyse tumor markers (CEA, CA125, CA15.3, CA19.9, CYFRA 21-1, and NSE) for metastasis detection in lung cancerpatients. METHODS: Serum tumor markers from 73 lung cancerpatients were measured before they were diagnosed. After lung cancer diagnosis, tumor markers were analyzed for the detection of distant metastases. RESULTS: In NSCLCpatients CYFRA 21-1 and NSE showed differences between stage IV and any of the other stages, p < 0.05. The accuracy for metastasis detection was AUC = 81.5 % for CYFRA 21-1 and AUC = 78.6 % for < 0.05) were independent predictors for metastasis presence. No tumor marker showed significant differences according to stages in SCLCpatients. CONCLUSIONS: CYFRA 21-1 could be used as a screening tool for metastasis detection in lung cancerpatients without symptoms of metastasis as well as CYFRA 21-1 and NSE in NSCLCpatients.
Authors: Álvaro Ruibal; Pablo Aguiar; María Carmen Del Río; Matilde Isabel Nuñez; Virginia Pubul; Michel Herranz Journal: Int J Mol Sci Date: 2015-02-18 Impact factor: 5.923
Authors: Nicolas Kahn; Julia Riedlinger; Markus Roeßler; Christina Rabe; Michael Lindner; Ina Koch; Sabine Schott-Hildebrand; Felix J Herth; Marc A Schneider; Michael Meister; Thomas R Muley Journal: Clin Proteomics Date: 2015-07-31 Impact factor: 3.988